Affiliations 

  • 1 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia
  • 2 Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia
  • 3 School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
  • 4 Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
  • 5 School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India
  • 6 Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India
  • 7 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
  • 8 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India
  • 9 Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia
  • 10 Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa
  • 11 Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto City, Japan
  • 12 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
J Food Biochem, 2021 01;45(1):e13572.
PMID: 33249629 DOI: 10.1111/jfbc.13572

Abstract

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. PRACTICAL APPLICATIONS: Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of Naringenin-loaded LCNs as an intervention would be of great interest to biological, formulation and respiratory scientists and clinicians.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.